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Abstract. We have identified an allelic deletion common
region in the q26 region of chromosome 10 in endometrial
carcinomas, which has been reported previously as a potential
target of genetic alterations related to this neoplasia. An
allelotyping analysis of 19 pairs of tumoral and non-tumoral
samples was accomplished using seven microsatellite
polymorphic markers mapping in the 10q26 chromosomal
region. Loss of heterozygosity for one or more loci was
detected in 29% of the endometrial carcinoma samples. The
observed pattern of loss enabled the identification of a 3.5 Mb
common deleted region located between the D10S587 and
D10S186 markers. An additional result from an endometrial
sample with evidence of a RER phenotype may suggest a more
centromeric region of loss within the above-mentioned interval.
This 401.84 Kb interval flanked by the D10S587 and D10S216
markers may be a plausible location for a putative suppressor
gene involved in early stage endometrial carcinogenesis.
Introduction
Uterine or endometrial cancer (EC) is the most common
gynaecological cancer and the seventh most common
malignant disorder worldwide. Its peak incidence occurs in
the post-menopausal age group, being ten times higher in
North America and Europe than in less developed countries. In
2001, EC accounted for 6% of all female cancers in the USA
and incidence is rising as life expectancy increases (1,2).
Inactivation of tumor suppressor genes (TSGs) is one of
the most critical steps leading to the development of cancer.
Alterations in TSGs usually involve an inactivating event at
one allele and the deletion of the remaining, together with
deletion of the flanking DNA regions (3). At the molecular
level, these deletions can be detected by loss of heterozygosity
(LOH) studies using polymorphic genetic markers. In
endometrial carcinoma, allelic deletions resulting in LOH have
been reported for multiple chromosomal arms (4,5). Losses
on chromosome 10 have been described, mainly in regions
q23 and q25-q26 (6-9). Located on q23.3, PTEN, phos-
phatase and tensin homolog, is the most frequently altered
tumor suppressor gene in endometrial carcinoma. Between
25 and 83% of endometrioid carcinomas are characterized by
the presence of PTEN abnormalities, mainly due to mutation
and/or allelic loss (10-12). In EC patients, mapping studies,
within the 10q25-q26 region, suggest the presence of more
than one TSG possibly involved in endometrial
tumorigenesis (7,13). This region has also been associated
with gliomas (14,15), prostate cancer (16,17) and melanomas
(18,19). Mapping allelic losses on this specific chromosomal
region may allow us to identify the involved TSGs in
endometrial carcinoma as well as in other cancers.
In a tumor subset, the observation of new microsatellite
alleles, absent in matching non-tumoral DNA, has led to the
discovery of the so-called microsatellite instability event
(20,21). As a marker for the replication error phenotype (RER),
microsatellite instability (MSI) has been commonly associated
with endometrial carcinoma (22). In sporadic endometrial
carcinoma, the MSI frequency varies, ranging from 15 to
45% (10,21,23).
In an attempt to localize a minimal critical region of loss
on 10q26, which could include a TSG involved in endometrial
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tumorigenesis, we performed an allelotyping analysis of 19
pairs of tumoral and non-tumoral DNA samples, using seven
microsatellite dinucleotide polymorphic markers, mapped to
the above-mentioned interval. As a complement, the studied
tumors have been screened for the RER phenotype.
Materials and methods
Tissue samples and DNA extraction. Endometrial carcinoma
samples from 19 patients were obtained from Santa Cruz
Hospital, S. José Hospital and Magalhães Coutinho Hospital,
all located in the Lisbon area. The 19 pairs of tumoral- and
corresponding non-tumoral tissue were paraffin-embedded.
The non-tumoral samples were non-neoplastic tissue adjacent
to the tumor and have all been histopathologically analysed
for the presence of infiltrating tumor cells. Specimens
consisted in adenocarcinomas classified according to the
World Health Organization (WHO) and staged according to
the International Federation of Gynecology and Obstetrics
(FIGO) system; ranging from stage IA (tumor limited to the
endometrium) to IIIA (tumor invades serosa and/or adnexa
and/or positive peritoneal cytology) and from grade 1 (well-
differentiated type) to grade 3 (poorly differentiated type).
Following mechanical disruption of tissue specimens, DNA
extraction was accomplished by standard SDS/proteinase-K
digestion and phenol/chloroform/isoamylic alcohol procedure
(37). DNA isolation of some samples was accomplished with
the QIAamp Tissue kit (Qiagen).
Microsatellite markers and PCR. For the allelotyping analysis
of endometrial carcinoma samples, seven informative
dinucleotide markers, spanning, ~14.5 Mb at the 10q26
chromosomal band: cen-D10S1236-D10S587-D10S216-
D10S575-D10S186-D10S217-D10S212-tel were used.
Information about the markers and primer sequences was
obtained from public databases [Genome Database
(http://www.gdb.org) and Ensembl Genome Browser
(http://www.ensembl.org/Homo_sapiens/)]. PCR reactions
were optimized over a range of 1.0-2.0 mM MgCl2 and
consisted of the following, for a total volume of 20 μl: Buffer
II 1X (50 mM KCl; 10 mM Tris-HCl, pH 8.3; Applied
Biosystems) at the appropriate MgCl2 concentration, 200 mM
dNTPs, 10 pmol of each primer, 0.5 U AmpliTaq Gold DNA
Polymerase (Applied Biosystems) and 100-200 ng genomic
DNA. One primer of each pair was fluorescence 5'-labelled
with fluorochrome FAM, TET or HEX. PCR reactions were
performed on a Perkin Elmer 9600 GenAmp PCR System
(Applied Biosystems), according to the following cycling
conditions: 20 sec at 94˚C, 30 sec at 55˚C and 40 sec at 72˚C
for 30 cycles, finalized by a 10 min extension step at 72˚C. In
order to rule out potential DNA contamination, negative
controls were included in every PCR reaction set. Fluorescent
PCR products were loaded on 6% polyacrylamide-8M urea
denaturing gels and separated in an ABI Prism 377 DNA
automated sequencer (Applied Bioystems). The automatically
collected data was analyzed with Genescan software (Applied
Biosystems). For result confirmation, PCR products were
electrophoresed at least twice.
Allelotyping analysis. For a given marker, samples with two
different-sized alleles were defined as heterozygous, while
those exhibiting one single allele were considered homozygous;
only heterozygous patients were regarded as informative. Ratio
comparison between tumoral (T) and non-tumoral (N) matched
tissue was accomplished using the (T1/T2)/(N1/N2) formula,
where T1 and N1 are the peak heights of the smaller allele and
T2 and N2 the peak heights of the larger allele, respectively
(24). For an allelic ratio <0.67 or >1.5 a sample was scored as
showing LOH (25). MSI was defined by the presence of altered
and/or additional alleles in the tumor DNA PCR-amplified
product, as compared with matched non-tumoral DNA. In case
MSI was present in at least two of the seven tested loci, the
RER-positive phenotype was attributed.
Results
Nineteen endometrial cancers were analysed for evidence of
LOH and MSI using fluorescence-based allelotyping with
seven (CA) repeated polymorphic markers spanning the 10q26
region.
Allelic loss and MSI were determined by comparing
tumoral- and non-tumoral DNA microsatellite allele profiles.
In two of the studied samples (numbers 5 and 27), and for
most of the analysed loci, we found the characteristic MSI
pattern, with additional alleles present in tumor DNA but not
in matched non-tumoral DNA (Fig. 1). Those samples were
considered as having a RER phenotype and, therefore, have
not been screened for LOH. At one locus, one sample,
exhibiting heterozygosity retention, has also showed MSI.
A total of 5 out of 17 tumors (29%) demonstrated allelic
loss for at least one of the l0q26 analysed loci. Of these, two
tumors (40%) showed LOH for all the informative markers
(samples no. 1 and 29), suggesting a total deletion of the
chromosomal region under study. The three remaining
tumors (60%) showed regional chromosomal losses with
retention of heterozygosity for some of the markers. Fig. 2
shows all cases with at least one allelic deletion. Examples of
allelic loss and heterozygosity retention are shown in Fig. 3.
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Figure 1. Example of microsatellite instability in endometrial carcinoma.
Novel alleles are present in the tumour sample but not in the matched non-
tumoral tissue. Arrows indicate constitutional alleles. The smaller peak on
the left hand side of the main peaks consists of a stutter band.
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Tumor samples with partial allelic deletions, corresponding
to sample numbers 33 and 45 enabled us to define a common
region of loss, on which a TSG may be located. Tumor no. 33
enabled the characterization of a 4.25 Mb smallest region of
deletion, located between markers D10S587 and Dl0S217,
cytogenetically mapped on l0q26.13 and 10q26.2, respectively.
Sample no. 45 delimited a 3.50 Mb minimal region of deletion
flanked by markers D10S587 and D10S186. Sample no. 27
showed retention of heterozygosity for marker D10S216
(Fig. 3b); therefore, if we include it in the LOH analysis, the
region of loss is shortened to 401.84 Kb, being delimited by
markers D10S587 and D10S216.
According to their histological grade and stage, tumors
have also been evaluated for LOH and MSI but no correlation
has been observed. It is, however, important to highlight the
detection of allelic losses in early stage development tumors
(sample numbers no. 1, 3 and 39).
Discussion
Previous cytogenetic and molecular genetic studies have
described the involvement of chromosome 10 in endometrial
carcinoma and identified the l0q23-q26 interval as being the
most plausible region to contain a tumor suppressor gene
involved in this type of cancer (6-9). For all endometrial
samples that showed evidence of loss in the 10q26 region
(5/17-29%), we were able to detect a common deleted region
spanning 3.5 Mb, located between markers D10S587 and
D10S186. Considering the results obtained with sample no. 27
(a RER sample which showed MSI for five out of the seven
analysed loci), which clearly exhibits heterozygosity
retention for marker D10S216 (Fig. 3b), that region may
further be narrowed to 401.84 Kb. These results suggest
that the region flanked by markers D10S587 and D10S216
may harbour a TSG involved in endometrial carcinoma
tumorigenesis.
Several molecular studies have lead to the identification
of genes putatively involved in various types of cancer mapped
in the l0q23-q26 interval. In prostate cancer MXI1, located on
l0q24-q25, has been lost and/or mutated (17,26). DMBT1, on
10q25.3-26.1, has been deleted in brain tumors and frequently
appears inactivated in digestive tract, lung, breast and
epithelial cancers (27-32). MMAC1/PTEN, on 10q23, appears
mutated in endometrial, brain, prostate, bladder and breast
cancers (10-12,33-37). All these genes are located in
chromo-somal regions different from the one defined in the
present study, suggesting a different TSG which may also be
involved in endometrial tumorigenesis. The 401.84 Kb
region delimited in this study overlaps that located between
markers D10S587 and D10S216, previously identified in
glioma by Rasheed et al (15). Our results confirm the
importance of a 10q26 chromosomal region in cancer, which
may contain, at least, one tumor suppressor gene involved in
the development of endometrial carcinoma, as well as of
other malignancies.
Previous studies have reported MSI as being a relative
common genetic event in both sporadic and inherited forms of
endometrial carcinoma (10,20). In the present study, we
found MSI in 15.8% (3/19) of the studied tumors.
Supposing endometrial tumors of higher grades and stages
of malignancy could result from the accumulation of genetic
alterations through a development pathway, some of these
alterations could also be expected to occur in early stage and
lower grade endometrial tumors. Therefore, the identification
in early stage tumor samples of allelic losses in the region
here described, suggests that this event may consist in an
early genetic pathway modification leading to endometrial
carcinogenesis.
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Figure 2. Allelic deletion map for seven 10q26 microsatellite markers in 7 out
of 19 endometrial carcinoma samples that showed LOH at one or more marker
loci. Markers have been arranged from centromere to telomere. Physical
map positions and chromosomal distances between markers are shown on the
right. Black boxes indicate LOH. Empty white boxes indicate heterozygosity
retention. Uninformative cases are vertical line extensions. Asterisks indicate
microsatellite instability.
Figure 3. (A) Example of LOH. When compared with non-tumoral tissue, the
smaller allele has been lost in the tumour sample (indicated by an arrow).
The residual signal, depicted on the lost allele, may be due to infiltrating
non-neoplastic cells. (B) Example of heterozygosity retention. Tumoral and
non-tumoral tissues show the same allele profile, with no evidence of allelic
loss.
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CIMAGO and Fundação para a Ciência e a Tecnologia,
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